Jeffrey Zonder, MD

Dr. Zonder is a Clinical Professor at Department of Oncology, Wayne State University School of Medicine. He is also a Medical Director at Apheresis Unit, Karmanos Cancer Hospital and Vice Chair at M1 IRB committee, Wayne State University. He received his medical degree from Wayne State University School of Medicine and completed residency from Primary Care Internal Medicine Residency Program, Strong Memorial Hospital. He completed fellowship in hematology/oncology at Wayne State University, Detroit Medical Center.

Dr. Zonder has special interest in multidisciplinary care of patients with multiple myeloma, as well as other hematologic cancers. In addition, he is focused on the investigation of therapies for multiple myeloma. His research interest includes investigation of new drug application for white cell disorders.

He is a member of American Society of Hematology, American Society of Clinical Oncology, Southwest Oncology Group, Multiple Myeloma and Special Populations Committees.

Representative Publications:

A Phase 1, Multicenter, Open-Label, Dose Escalation Study of Elotuzumab in Patients With Advanced Multiple Myeloma.
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/Ii Trial.
Dermatological Complications Following Initiation of Lenalidomide in a Patient with Chronic Lymphocytic Leukaemia.
Lenalidomide and High-Dose Dexamethasone Compared With Dexamethasone as Initial Therapy for Multiple Myeloma: A Randomized Southwest Oncology Group Trial (S0232).